BRPI9701248B1 - Compostos para a terapia de tumores e distúrbios inflamatórios, produto farmacêutico e formulação farmacêutica dos mesmos - Google Patents

Compostos para a terapia de tumores e distúrbios inflamatórios, produto farmacêutico e formulação farmacêutica dos mesmos

Info

Publication number
BRPI9701248B1
BRPI9701248B1 BRPI9701248A BR9701248A BRPI9701248B1 BR PI9701248 B1 BRPI9701248 B1 BR PI9701248B1 BR PI9701248 A BRPI9701248 A BR PI9701248A BR 9701248 A BR9701248 A BR 9701248A BR PI9701248 B1 BRPI9701248 B1 BR PI9701248B1
Authority
BR
Brazil
Prior art keywords
tumors
therapy
inflammatory disorders
compounds
pharmaceuticals
Prior art date
Application number
BRPI9701248A
Other languages
English (en)
Portuguese (pt)
Other versions
BR9701248A (pt
BR9701248A8 (pt
Inventor
Claude Monneret
Frederic Schmidt
Jean-Claude Florent
Joerg Czech
Klaus Bosslet
Manfred Gerken
Rainer Straub
Original Assignee
Aventis Pharma Deutschland Gmbh
Hoechst Ag
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8222555&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9701248(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Deutschland Gmbh, Hoechst Ag, Sanofi Aventis Deutschland filed Critical Aventis Pharma Deutschland Gmbh
Publication of BR9701248A publication Critical patent/BR9701248A/pt
Publication of BR9701248A8 publication Critical patent/BR9701248A8/pt
Publication of BRPI9701248B1 publication Critical patent/BRPI9701248B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
BRPI9701248A 1996-03-12 1997-03-11 Compostos para a terapia de tumores e distúrbios inflamatórios, produto farmacêutico e formulação farmacêutica dos mesmos BRPI9701248B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96103866 1996-03-12

Publications (3)

Publication Number Publication Date
BR9701248A BR9701248A (pt) 1999-10-13
BR9701248A8 BR9701248A8 (pt) 2013-06-18
BRPI9701248B1 true BRPI9701248B1 (pt) 2022-01-18

Family

ID=8222555

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9701248A BRPI9701248B1 (pt) 1996-03-12 1997-03-11 Compostos para a terapia de tumores e distúrbios inflamatórios, produto farmacêutico e formulação farmacêutica dos mesmos

Country Status (24)

Country Link
US (1) US5935995A (enExample)
EP (1) EP0795334B1 (enExample)
JP (1) JP4392065B2 (enExample)
KR (1) KR100466467B1 (enExample)
CN (1) CN1168733C (enExample)
AT (1) ATE316799T1 (enExample)
AU (1) AU708202B2 (enExample)
BG (1) BG61900B1 (enExample)
BR (1) BRPI9701248B1 (enExample)
CA (1) CA2199664C (enExample)
CZ (1) CZ297994B6 (enExample)
DE (1) DE59712561D1 (enExample)
DK (1) DK0795334T3 (enExample)
ES (1) ES2257756T3 (enExample)
HU (1) HU228764B1 (enExample)
NO (1) NO320322B1 (enExample)
NZ (1) NZ314368A (enExample)
PL (1) PL189604B1 (enExample)
RO (1) RO120951B1 (enExample)
RU (1) RU2191021C2 (enExample)
SG (1) SG50011A1 (enExample)
SI (1) SI0795334T1 (enExample)
TR (1) TR199700178A2 (enExample)
UA (1) UA50719C2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525606A (en) 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
CA2328614C (en) * 1999-02-12 2012-06-26 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
IL146284A0 (en) 1999-05-04 2002-07-25 Strakan Ltd Androgen glycosides and pharmaceutical compositions containing the same
US6191119B1 (en) * 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
DE10058596A1 (de) * 2000-11-25 2002-06-06 Aventis Pharma Gmbh Verfahren zum Screening von chemischen Verbindungen zur Modulierung der Wechselwirkung einer EVH1-Domäne oder eines Proteins mit einer EVH1-Domäne mit einer EVH1-Bindedomäne oder einem Protein mit einer EVH1-Bindedomäne sowie ein Verfahren zum Nachweis besagter Wechselwirkung
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US20060014697A1 (en) 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US6821998B2 (en) 2001-08-30 2004-11-23 Chemocentryx, Inc. Arylamines as inhibitors of chemokine binding to US28
AU2003244088A1 (en) * 2002-06-20 2004-01-06 Nippon Suisan Kaisha, Ltd. Produrg, medicinal utilization thereof and process for producing the same
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
US7160867B2 (en) * 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
WO2006038070A2 (en) * 2004-03-30 2006-04-13 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
US7825096B2 (en) * 2004-09-08 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs
ZA200800314B (en) * 2005-06-29 2009-09-30 Threshold Pharmaceuticals Inc Phosphoramidate alkylator prodrugs
KR20150139620A (ko) * 2007-04-06 2015-12-11 지오팜 온콜로지 인코포레이티드 이소포스포르아미드 머스타드의 염 및 이의 동족체
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
BR112012004720B1 (pt) * 2009-09-02 2021-06-29 Auckland Uniservices Limited Inibidores de cinase, seus usos, profármaco e composição farmacêutica que o compreende
KR101253399B1 (ko) 2010-10-26 2013-04-11 영남대학교 산학협력단 아포지단백질 ａ－ｉ 및 그 변이체를 포함한 재조합 고밀도지단백질을 이용한 라파마이신 제형
KR101628872B1 (ko) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
JP7120765B2 (ja) 2015-11-25 2022-08-17 レゴケム バイオサイエンシズ， インク． ペプチド基を含む複合体及びそれに関連する方法
HUE067016T2 (hu) 2015-11-25 2024-09-28 Ligachem Biosciences Inc Önfeláldozó csoportokat tartalmazó konjugátumok és ezekkel kapcsolos eljárások
CN107847605B (zh) 2015-11-25 2021-12-24 乐高化学生物科学股份有限公司 包含分支接头的抗体-药物缀合物及其相关方法
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
JP7664680B2 (ja) 2017-03-29 2025-04-18 リガケム バイオサイエンシズ， インク． ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物
KR20200118827A (ko) 2018-02-02 2020-10-16 마베릭스 온콜로지, 잉크. 젬시타빈 모노포스페이트의 소분자 약물 컨쥬게이트
US11827703B2 (en) 2018-05-09 2023-11-28 Legochem Biosciences, Inc. Compositions and methods related to anti-CD19 antibody drug conjugates
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3836676A1 (de) * 1988-10-28 1990-05-03 Hoechst Ag Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
CA2025899A1 (en) * 1989-01-23 1990-07-24 Reinhard Bredehorst Site specific in-vivo activation of therapeutic drugs
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
AU649421B2 (en) * 1990-05-18 1994-05-26 Sanofi-Aventis Deutschland Gmbh Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
EP0538799B1 (en) * 1991-10-25 1995-03-15 TUNGSRAM Részvénytársaság Single-capped low-pressure discharge lamp
DE4233152A1 (de) * 1992-10-02 1994-04-07 Behringwerke Ag Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
CA2081281A1 (en) * 1992-10-23 1994-04-24 Shing-Ming Wang Activation of glucuronide prodrugs by ligand-beta-glucuronidase conjugates for chemotherapy
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
DE4314556A1 (de) * 1993-05-04 1994-11-10 Behringwerke Ag Modifizierte Antikörperenzymkonjugate und Fusionsproteine sowie ihre Anwendung zur tumorselektiven Therapie
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie

Also Published As

Publication number Publication date
JP4392065B2 (ja) 2009-12-24
MX9701832A (es) 1998-07-31
NZ314368A (en) 1998-10-28
BG101290A (en) 1997-09-30
US5935995A (en) 1999-08-10
BR9701248A (pt) 1999-10-13
EP0795334A3 (de) 1997-09-24
UA50719C2 (uk) 2002-11-15
NO971116D0 (no) 1997-03-11
AU1620597A (en) 1997-09-18
DE59712561D1 (de) 2006-04-13
HUP9700579A3 (en) 1999-05-28
DK0795334T3 (da) 2006-06-06
RU2191021C2 (ru) 2002-10-20
NO320322B1 (no) 2005-11-21
BG61900B1 (bg) 1998-09-30
JPH101495A (ja) 1998-01-06
HUP9700579A2 (en) 1997-12-29
CN1168733C (zh) 2004-09-29
ATE316799T1 (de) 2006-02-15
ES2257756T3 (es) 2006-08-01
CZ74297A3 (en) 1997-09-17
KR100466467B1 (ko) 2005-06-29
CZ297994B6 (cs) 2007-05-16
TR199700178A2 (tr) 1997-09-21
CN1163895A (zh) 1997-11-05
NO971116L (no) 1997-09-15
SG50011A1 (en) 1998-06-15
HU9700579D0 (en) 1997-04-28
CA2199664A1 (en) 1997-09-12
BR9701248A8 (pt) 2013-06-18
PL318878A1 (en) 1997-09-15
RO120951B1 (ro) 2006-10-30
PL189604B1 (pl) 2005-08-31
EP0795334B1 (de) 2006-02-01
AU708202B2 (en) 1999-07-29
EP0795334A2 (de) 1997-09-17
HU228764B1 (en) 2013-05-28
CA2199664C (en) 2008-05-20
SI0795334T1 (sl) 2006-06-30
KR970065550A (ko) 1997-10-13

Similar Documents

Publication Publication Date Title
BR9701248A (pt) Novos pró-medicamentos para a terapia de tumores e distúrbios inflamatórios
BR9909565A (pt) Derivados bicìclicos do ácido hidroxâmico
BR9804437A (pt) Compostos para a osteoporose
BR9812753A (pt) Combinação farmacêutica, uso da mesma, processo para tratamento de uma doença inflamatória, e, composição farmacêutica
BR0008922A (pt) Compostos úteis como agentes antiinflamatórios
BR9713186A (pt) Inibidores de metaloprotease 1,3-diheterocìclicos
DK1014966T3 (da) Farmaceutisk præparat til behandling af neurologiske og neuropsykiatriske lidelser
BR9813028A (pt) Agonistas de prostaglandina e seu uso para tratar distúrbios nos ossos
BR9902086A (pt) Formulações farmacêuticas.
PT1259512E (pt) Compostos de pteridin para o tratamento da psoriase
BR0208957A (pt) Ciclobuteno-1,2-dionas 3,4-dissubstituìdas como ligandos de receptor de quimiocina cxc
BR9814592A (pt) "compostos azopolicìclicos condensados com arila"
BR9805544C1 (pt) Uso de um composto.
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
PT705100E (pt) Guanidinas substituidas terapeuticas
BR0114344A (pt) Retinóides para o tratamento de enfisema
BR9907655A (pt) Derivados de ácido di-hidróxi-hexanóico
SE9804212D0 (sv) Compounds
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
CU23088A3 (es) Compuestos de tetra-hidropiridina.
SE9802937D0 (sv) Novel compounds
AU4179399A (en) Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
NO983511D0 (no) Difenylstilbener som pro-legemidler for COX-2-inhibitorer
BR9806083A (pt) Composi-Æo farmac-utica para o tratamento da hapattite c

Legal Events

Date Code Title Description
PC Transfer

Free format text: AVENTIS PHARMA DEUSTSCHLAND GMBH (DE)

HHT Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication

Free format text: TRANSFERIDO DE: HOECHST AKTIENGESELLSCHAFT - REFERENCIA RPI NO. 1587 DE 05/06/2001 COD. 25.1 - ITEM71

B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: PUBLICACAO ANULADA REFERENTE RPI 2209 DE 07/05/2013.POR TER SIDO INDEVIDA.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/06/2013, OBSERVADAS AS CONDICOES LEGAIS.

B03H Publication of an application: rectification [chapter 3.8 patent gazette]

Free format text: REFERENTE A RPI 1501 DE 13/10/1999, QUANTO AO ITEM (30 E 72), CONFORME SOLICITADO NA PETICAO NO18504/RJ DE 25/08/1997.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061553/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132273-17.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU:OSI PHARMACEUTICALS, LLC , PFIZER, SANOFI-AVERTI, , SANOFI-AVERTI DEUTCHLAND GMBH, SCHERING CORPORATION.

B15K Others concerning applications: alteration of classification

Ipc: A61K 47/54 (2017.01)

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 11/03/2017, CONFORME DETERMINADO NO INPI-52400.061553/2013-52 SECAO JUDICIARIA DO RIO DE JANEIRO 9A VARA FEDERAL DO RIO DE JANEIRO PROCESSO : NO 0132273-17.2013.4.02.5101.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.1 NA RPI NO 2543 DE 01/10/2019 POR TER SIDO INDEVIDA.

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI NO 52402.005802/2020-39 TRIBUNAL REGIONAL FEDERAL DA 2A REGIAO PROCESSO : NO 5004917-81.2020.4.02.0000/RJ REQUERENTE: MERCK SHARP AND DOHME CORPORATION REQUERENTE: PFIZER PRODUCTS REQUERENTE: OSI PHARMACEUTICALS, LLC. REQUERIDO: INPI-INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL MPF: MINISTERIO PUBLICO FEDERAL AMICUS CURIAE: ASSOCIACAO BRAS DAS IND DE Q FINA B E SUAS ESP ABIFINA AMICUS CURIAE: INTERFARMA ASSOCIACAO DA INDUSTRIA FARMACEUTICA DE PESQUISA INTERESSADO: SANOFI-AVENTIS DEUTSCHLAND GMBM INTERESSADO: SANOFI AVENTIS INTERESSADO: ZOETIS LLC DECISAO: ANTE O EXPOSTO, ATRIBUO EFEITO SUSPENSIVO A APELACAO INTERPOSTA NO PROCESSO NO 0132273-17.2013.4.02.5101 POR OSI PHARMA

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/03/1997, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.